Omega-3 supplementation effects on polycystic ovary syndrome symptoms and metabolic syndrome
Department of Obstetrics and Gynecology, Student Research Committee, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
| ORIGINAL ARTICLE | |
|
Omega-3 supplementation effects on polycystic ovary syndrome symptoms and metabolic syndrome
Behnaz Khani1, Farahnaz Mardanian1, Sajadeh Jafari Fesharaki2
1 Department of Obstetrics and Gynecology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
2 Department of Obstetrics and Gynecology, Student Research Committee, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
| Date of Submission | 13-Sep-2016 |
| Date of Decision | 09-Nov-2016 |
| Date of Acceptance | 25-Feb-2017 |
| Date of Web Publication | 30-May-2017 |
| Abstract |
Background: Polycystic ovary syndrome (PCOS) is the most common female endocrine disorder with unknown etiology and with different complications. The aim of this study was to evaluate the effect of omega-3 supplementation on PCOS symptoms and metabolic syndrome. Materials and Methods: This double-blind clinical trial was performed in 2015 in Alzahra and Shahid Beheshti Hospitals, Isfahan, Iran, on 88 patients with PCOS. Intervention group took omega-3 supplements with dose of 2 g/day for 6 months (two capsules), but control group received two olive oil capsules. Finally, ultrasound and laboratory findings and the recovery rate of menstrual disorders in both groups were compared. Results: After 6 months' intervention, waist circumference (WC) was significantly lower in omega-3 as compared to control (81.18 ± 2.87 vs. 84.22 ± 2.61 cm, respectively,P< 0.0001). High-density lipoprotein was increased (47.2 ± 1.37 vs. 41.56 ± 1.34 mg/dl, respectively,P< 0.0001) while low-density lipoprotein (107.79 ± 1.68 vs. 117.4 ± 1.57 mg/dl, respectively), triglyceride (116.02 ± 3.13 vs. 125.06 ± 2.91 mg/dl, respectively), and cholesterol (180.34 ± 6.34 vs. 189.56 ± 5.93 mg/dl, respectively) in omega-3 were significantly lower than control (P < 0.0001). The interval between periods in omega-3 was significantly shorter than control (29.83 ± 4.68 vs. 47.11 ± 8.72 days, respectively,P< 0.001). Conclusion: Omega-3 decrease lipid profiles, WC, and interval between periods while weight, hip circumference, fasting blood sugar, number of ovarian follicle, size of ovary, bleeding volume, menstrual bleeding, and hirsutism score did not change by administration of omega-3.
Keywords: Metabolic syndrome, omega-3, polycystic ovary syndrome
http://www.jmsjournal.net/article.asp?issn=1735-1995;year=2017;volume=22;issue=1;spage=64;epage=64;aulast=Khani
